bcd-132
mAbexperimental
Clinical trial activity
7 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
5
Phase 3
4
Phase 4
0
Earliest trial started Feb 22, 2018 (NCT03551275)
Timeline
Indications
Mechanism of action
- B-lymphocyte antigen CD20INHIBITOR
MS4A1 inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5314981 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07136389 | Phase 1 | Mar 27, 2025 | Biocad |
| NCT05726630 | Phase 3 | Dec 26, 2022 | Biocad |
| NCT05730699 | Phase 3 | Dec 12, 2022 | Biocad |
| NCT06987851 | Phase 3 | Mar 22, 2022 | Biocad |
| NCT05385744 | Phase 3 | Apr 5, 2021 | Biocad |
| NCT04056897 | Phase 2 | Jun 7, 2019 | Biocad |
| NCT03551275 | Phase 1 | Feb 22, 2018 | Biocad |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Biocad | For profit | 7 | 7 | 3 | 2018 |
1 organizations
Page 1 / 1